IDEAS home Printed from
   My bibliography  Save this paper

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures


  • Pearson, S.


The Institute for Clinical and Economic Review (ICER) is an independent organisation founded in the US in 2006. Its remit is to evaluate the clinical and economic value of health care interventions − prescription drugs, diagnostic tests, and a range of others − and innovations in the delivery of care. ICER involves key stakeholders including patients, doctors, life science companies, private insurers, and the government to help ensure its research informs important policy decisions. Regional independent appraisal committees hold public hearings on each report. All reports are publicly available without charge. One of ICER's core areas of activity is drug assessment reports that incorporate data on efficacy, economic value, and other elements of value important to patients and their families. The reports provide a "value-based price benchmark" meant to indicate drug pricing that encourages improved patient outcomes not just today, but over the longer term. ICER's reports also evaluate the potential short-term budget impact of new drugs to alert payers and policy makes in situations where short-term costs may strain health system budgets or threaten patient access. To avoid conflicts of interest, all ICER reports are produced with funding exclusively from non-profit foundations and other independent sources. Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available publicly. This is exciting, but also offers serious and critical challenges in valuation. The focus of this seminar briefing is on those challenges.

Suggested Citation

  • Pearson, S., 2019. "Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures," Seminar Briefings 002112, Office of Health Economics.
  • Handle: RePEc:ohe:sembri:002112

    Download full text from publisher

    File URL:
    Download Restriction: no

    More about this item


    Economics of Innovation; Value; Affordability; and Decision Making;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    NEP fields

    This paper has been announced in the following NEP Reports:


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:sembri:002112. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Publications Manager). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.